Department of Neurology, General Hospital of Northern Theater Command
Shenyang, 110016, China
NCT Number: NCT04752631
This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis for stroke beyond time window by Tenecteplase (TNK-tPA). This exploratory study was to describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Shenyang, 110016, China
In patients with acute stroke with an unknown time of onset, intravenous alteplase guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia resulted in a significantly better functional outcome at 90 days. This trial will enroll acute ischemic stroke patients within 4.5 to 24 hours of onset. All the patients had an ischemic lesion that was visible on MRI diffusion-weighted imaging but no parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR), which indicated that the stroke had a ischemic penumbra. Randomization will be 1:1 to TNK-tPA (experimental) or standard treatment (control), in compliance with guidelines for acute stroke. Clinical outcome was assessed by disability on the basis of the modified Rankin scale at 90 days follow-up, which will be performed by a blinded assessor.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The participants received TNK-tPA thrombolytic therapy
Other names: TNK-tPA
Time frame: 90 Days
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
Time frame: 90 Days
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
Time frame: 90 Days
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
Time frame: 24 hours and 1 week
the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome
Time frame: 90 Days
The incidence of stroke and other vascular events
Time frame: 14 days
death due to any cause
Time frame: 48 hours
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Time frame: 48 hours
Proportion of PH1 and PH2 within 48 hours after the treatment
Time frame: 7 Days
Intracranial hemorrhage assessed by MRI/CT
Time frame: 7 Days
proportion of any bleeding events
General Hospital of Shenyang Military Region
Other
MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study
Acronym: ROSE-TNK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details